NCT00973323已完成2 期
BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 100
- 主要终点
- (Safety) Incidence of bleeding
研究概览
简要总结
This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese subjects with non-valvular AF who met all of the following criteria:
- •Persistent or paroxysmal non-valvular AF with >/=2 episodes before enrollment, at least 1 of which had been verified by ECG recording within 4 weeks before randomization
- •Male subjects aged 20 years or older and postmenopausal female subjects
- •Subjects with at least one risk factor for thromboembolism or aged 60 years or older (Risk factor for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, congestive heart failure).
排除标准
- •History or presence of stroke or transient ischemic attack.
- •History of intracerebral hemorrhage.
- •History or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.
研究组 & 干预措施
Arm 1
Experimental
干预措施: Xarelto (Rivaroxaban, BAY59-7939) (Drug)
Arm 2
Experimental
干预措施: Xarelto (Rivaroxaban, BAY59-7939) (Drug)
Arm 3
Experimental
干预措施: Xarelto (Rivaroxaban, BAY59-7939) (Drug)
Arm 4
Active Comparator
干预措施: Warfarin (Drug)
结局指标
主要结局
(Safety) Incidence of bleeding
时间窗: Throughout treatment and followup period
(PK/PD) BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST
时间窗: Day 14 and Day 28
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
BAY59-7939 in Atrial Fibrillation Once Daily (OD)Atrial FibrillationNCT00973245Bayer102
已完成
2 期
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging StudyVenous ThromboembolismNCT00402467Bayer613
进行中（未招募）
1 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein ThrombosisODIXa-DVTA prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial. - ODIXa-DVTEUCTR2004-001083-43-GBBayer HealthCare AG
已完成
2 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. A phase II dose finding and proof of principle trial.ODIXa-DVTDeep vein thrombosisCardiovascular - Other cardiovascular diseasesACTRN12605000601639Bayer Australia Ltd600
进行中（未招募）
1 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein ThrombosisODIXa-DVTA prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial. - ODIXa-DVTEUCTR2004-001083-43-HUBayer HealthCare AG